Successful treatment with belimumab of severe systemic lupus erythematosus not responding to standard therapy: a case report

Ottavia Magnani, Elena Penza, Giuseppe Murdaca, Francesco Puppo

DOI: https://doi.org/10.7175/cmi.v10i1.1227

Abstract

 

Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by complex pathophysiology and heterogeneous clinical picture. Belimumab is the first biological therapy licensed for SLE.

We report the case of a 24 years old woman affected by a severe form of systemic lupus erythematosus with arthritis, muscle weakness, cervical lymphadenopathy, cutaneous involvement, fever, leukopenia, low complement levels and positivity for anti-dsDNA antibodies. Treatment with high dose steroids, hydroxychloroquine, and mycophenolate mofetil did not induce remission and several disease flares were observed. Therapy with anti-BLys monoclonal antibody belimumab leads to a fast clinical and laboratory response and to stable remission lasting for 30 months allowing steroid tapering to very low maintenance dose. 

Keywords

Systemic Lupus Erythematosus (SLE); Belimumab; Biological Therapy

Full Text

HTML PDF

References

  • Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011; 365: 2110-21; y of hepatitis B. Semin Liver Dis 2005; 25: 3-8; http://dx.doi.org/10.1056/NEJMra1100359
  • Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677-86; http://dx.doi.org/10.1002/art.34473
  • Kuhn A, Bonsmann G, Anders H, et al. The Diagnosis and Treatment of Systemic Lupus Erythematosus. Dtsch Arztebl Int 2015; 112: 423-32; http://dx.doi.org/10.3238/arztebl.2015.0423
  • Bertsias G, Ioannidis JPA, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008; 67: 195-205; http://dx.doi.org/10.1136/ard.2007.070367
  • Burness CB, McCormack PL. Belimumab: in systemic lupus erythematosus. Drugs 2011; 71: 2435-44; http://dx.doi.org/doi:10.2165/11208440-000000000-00000
  • Hahn BH. Belimumab for Systemic Lupus Erythematosus. N Engl J Med 2013; 368: 1528-35; http://dx.doi.org/10.1056/NEJMct1207259
  • Wallace DJ, Navarra S, Petri MA, et al. for the BLISS-52 and -76, and LBSL02 Study Groups. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus 2013; 22 : 144-54; http://dx.doi.org/10.1177/0961203312469259.
  • Ginzler EM, Wallace DJ, Merrill JT, et al. for the LBSL02/99 Study Group. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol 2014; 41 : 300-9; http://dx.doi.org/10.3899/jrheum.121368
  • Ruiz-Arruza I, Ugarte A, Cabezas-Rodriguez I, et al. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2014; 53: 1470-76 http://dx.doi.org/10.1093/rheumatology/keu148

Statistics

Abstract: 1354 views
HTML: 1243 views
PDF: 300 views

Refbacks

  • There are currently no refbacks.